Stock Taper 
ANIP
$75.35
▼ DOWN 2.55% (-1.97)
KEY STATISTICS
Market Cap$1.71 B
52w High$99.50
52w Low$70.15
Dividend Yield—
Frequency—
P/E9.17
Volume379.16K
Shares Out.22.73M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Nikhil Lalwani
COMPENSATION 2026
Salary$837,409
Stock Awards$7,848,711
Incentive Plan Pay$1,572,500
All Other Comp.$20,000
Total$10,278,620
ABOUT
SECTOR
Healthcare
WENT PUBLIC
May 5, 2000
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
970
PRICE TARGET
Target High$119.00
Target Low$90.00
Target Median$104.50
Target Consensus$104.50
UPCOMING EARNINGS
DateNov 6, 2026
DayFriday
Rev. Est.$280.06M
NOV
6
FRI
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2013-07-18 | Reverse | 1:6 |
| 2012-06-04 | Reverse | 1:6 |
| 2002-06-03 | Reverse | 1:10 |
PRICE
$75.35 ▼ DOWN 2.55% (−$1.97)About ANI Pharmaceuticals, Inc.
https://www.anipharmaceuticals.com ↗ANI Pharmaceuticals, Inc. develops, manufactures, and markets branded and generic prescription pharmaceuticals, including controlled substances and specialty products, primarily in the U.S. and Canada, serving various distribution channels since 2...
INDUSTRY
Drug Manufacturers - Specialty & Generic
A PRODUCT ANI PHARMACEUTICALS, INC. IS KNOWN FOR
Purified Cortrophin Gel
Purified Cortrophin Gel, an injectable therapy for autoimmune and inflammatory disorders like MS, RA, and nephrotic syndrome, is a key growth driver for ANI Pharmaceuticals' Rare Disease segment, with ongoing FDA-approved delivery innovations.
Revenue by Products
| Icon | PRODUCT | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
 | Sales of rare disease pharmaceutical products | $118.45M | $131.27M ▲ | $94.37M ▼ | $135.84M ▲ |
 | Total Sales of Generics and Other | $98.69M | $103.47M ▲ | $109.22M ▲ | $100.66M ▼ |
 | Sales of Established Brands | $10.68M | $12.31M ▲ | $12.33M ▲ | $11.81M ▼ |
Revenue by Geography
| Map | REGION | Q1-2024 | Q2-2024 | Q3-2024 | Q4-2024 |
|---|---|---|---|---|---|
 | UNITED STATES | $137.43M | $138.04M ▲ | $147.12M ▲ | $182.4M ▲ |
 | NonUS | — | — | $1.22M | $8.17M ▲ |
ETFS HOLDING THIS STOCK
ETFS HOLDING
192
LISTED HERE
26
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
58.22%
HOLDERS
429
TOP 12 OF 429 · RANKED BY POSITION SIZE
Blackrock, Inc.
Blackrock Inc.
Vanguard Group Inc
Soleus Capital Management, L.P.
State Street Corp
Blackrock Fund Advisors
Tang Capital Management LLC
Goldentree Asset Management LP
Global Alpha Capital Management Ltd.
Dimensional Fund Advisors LP
Deep Track Capital, LP
Millennium Management LLC
RATINGS SNAPSHOT
Overall rating: B-
Discounted Cash Flow1
Return On Equity4
Return On Assets4
Debt To Equity2
Price To Earnings2
Price To Book2
Overall Score3
INSIDER TRADES
★
OFFICER: SR. VP, GENERAL COUNSEL & SEC.
Cook Meredith
Sale · 500 shares
2026-08-13
★
OFFICER: SVP, GENERICS
Gutwerg Ori
Sale · 3.2K shares
2026-08-10
★
OFFICER: SVP & CFO
CAREY STEPHEN P.
Sale · 2.9K shares
2026-07-29
★
OFFICER: SR. VP, GENERAL COUNSEL & SEC.
Cook Meredith
Sale · 2.5K shares
2026-07-18
MOST RECENT ANALYST GRADES
GRADE SUMMARY
HOLD 2
BUY 2
OVERWEIGHT 1
5 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 HROW | $40.95 | COMPARE |
 TLRY | $4.84 | COMPARE |
 BGM | $0.26 | COMPARE |